ライフサイエンスコーパス: HIV-positive

1 positive at diagnosis, and 10/109 (9%) were HIV positive.

2 8%) patients were male, and 2,243 (61%) were HIV positive.

3 88 patients were recruited, 132 of whom were HIV positive.

4 tus established, of whom 11 964 (10.2%) were HIV positive.

5 d in 29 (26%) of patients, and 28 (25%) were HIV positive.

6 nd virological suppression in adults who are HIV positive.

7 ed 117 patients; 68.4%(95%CI:59.3-76.3) were HIV positive.

8 years, 586 of whom were HIV-negative and 535 HIV-positive.

9 ears, 58 (57%) were female and 89 (87%) were HIV-positive.

10 81% of eligible household members), 29% were HIV-positive.

11 dmissions from 2006-2016, 19,039 (2.1%) were HIV-positive.

12 reviously identified and newly identified as HIV-positive.

13 334 women had 30,291 pregnancies: 3,339 were HIV-positive, 10,958 were HIV-negative, and 15,994 had u

14 ), having a partner suspected or known to be HIV positive (11.7, 6.0-22.5), and having two or more li

15 participants, 88% with cavitary disease, 20% HIV-positive, 16 with isoniazid-sensitive and 41 with is

16 Among 3,460,932 patients (16% HIV positive), 22,308 were diagnosed with COVID-19, of w

17 at baseline, 30% at the follow-up visit) and HIV-positive (27% at baseline, 35% at the follow-up visi

18 5142 participants were HIV-positive (2703 [13.7%] in inland and 2439 [40.1%] in

19 Median age was 41.9 years, 89% were HIV positive (+) (42/47) and 85% (40/47) were male, 58%

20 erall, 46 male partners were confirmed to be HIV positive, 42 (91.3%) of whom initiated ART within 28

21 Of the 668 children, 22 (3%) were HIV-positive, 594 (89%) HIV-exposed uninfected, and 52 (

22 iated with reported male-partner HIV status (HIV-positive 67%, -negative 39%, unknown 31%; overall ef

23 70%, 68%, and 51%, respectively), more were HIV positive (83%, 65%, 34%, and 50%), fewer were virall

24 iated with reported male-partner HIV status (HIV-positive 94%, unknown 35%, HIV-negative 8%; p < 0.00

25 In human immunodeficiency virus (HIV)-positive adults, low CD4 cell counts despite fully

26 We evaluated HIV-positive adults >=18 years old newly initiating ART

27 We enrolled HIV-positive adults (aged >=18 years) who presented for

28 Eligible participants were HIV-positive adults (aged >=18 years) with CD4 counts of

29 cts of achieving the UNAIDS target of 95% of HIV-positive adults diagnosed by 2030.

30 ociated with substantial excess mortality in HIV-positive adults in Cape Town.

31 ancial incentives on viral suppression among HIV-positive adults in rural Uganda.

32 The estimated percentage of HIV-positive adults in the community who were receiving

33 In this study, we found that among HIV-positive adults newly initiating ART, mortality amon

34 udy, we analysed routinely collected data on HIV-positive adults receiving antiretroviral therapy (AR

35 simplify treatment and improve outcomes for HIV-positive adults receiving ART in resource-limited se

36 Of 6,197 HIV-positive adults referred by CHiPs, 42% (95% CI: 40%-

37 In this multicenter study, we followed HIV-positive adults who had mounted seroresponses after

38 ed via standardised paper-based surveys with HIV-positive adults who were neither pregnant nor breast

39 levels in CSF and plasma specimens from 220 HIV-positive adults who were taking suppressive ART.

40 ised, placebo-controlled trial, we recruited HIV-positive adults with cryptococcal meningitis from tw

41 A cohort of HIV-positive adults with laboratory-confirmed TB from th

42 f these treatments altered mortality risk in HIV-positive adults with multidrug-resistant tuberculosi

43 accination might be warranted, especially in HIV-positive adults with predictors of early seroreversi

44 ves had no effect on viral suppression among HIV-positive adults.

45 Adult, nonpregnant, HIV-positive, ambulatory patients presenting for any HIV

46 Persons who are HIV positive and taking ART and persons taking PrEP to p

47 ome-wide association study of eGFR among 567 HIV-positive and 117 HIV-negative male participants in t

48 oximately half of 40 tumor specimens from 23 HIV-positive and 17 HIV-negative patients (29 men and 11

49 apart from 211 Nigerian women (67%, 142/211 HIV-positive and 33%, 69/211 HIV-negative) and evaluated

50 4 years of follow-up was assessed among 598 HIV-positive and 550 comparable HIV-negative participant

51 480 of 1425 (36.1%, 95% CI 33.6-38.6) HIV-positive and 784 of 2850 (27.5%, 95% CI 25.9-29.2) H

52 First, blood samples from HIV-positive and a comparison group of infection-nonreac

53 the greatest comorbidity disparities between HIV-positive and HIV-negative admissions were mild liver

54 HIV-positive and HIV-negative individuals aged 18 years

55 ifies transmission of N. gonorrhoeae between HIV-positive and HIV-negative individuals receiving pre-

56 ts in the 15 intervention clusters, who were HIV-positive and not already taking ART were offered uni

57 were HIV-positive and on ART, 886 (7%) were HIV-positive and not on ART, and 1749 (15%) had extensiv

58 2997 (25%) were HIV-positive and on ART, 886 (7%) were HIV-positive and

59 Among 547 participants, 102 (19%) were HIV positive, and 35 (6%) had an unsuccessful outcome.

60 ntion arm and none in the control arm tested HIV positive, and 8 sexual partners of intervention arm

61 -42.5), 239 (38%) were women, 272 (43%) were HIV-positive, and 69 (11%) patients died.

62 of individuals who were newly identified as HIV-positive as a proportion of all individuals previous

63 80.2% (210/262) of those who knew they were HIV-positive at hospital admission were taking antiretro

64 48.5% of ocular syphilis cases were HIV-positive at the time of syphilis diagnosis, compared

65 All HIV-positive attendees (index patients) at six urban and

66 11 suggest that the pooled proportion of MSM HIV-positive aware has remained low (18.5%, 12.5-25.3; 2

67 60.1% (48.6-71.1; five estimates) among MSM HIV-positive aware of their status.

68 However, HIV-positive blacks continue to have much higher rates o

69 positive), and HIV prevalence (proportion of HIV-positive children among those tested).

70 g disease (CLD) is a common co-morbidity for HIV-positive children and adolescents on antiretroviral

71 Thus, HIV-positive children harbor distinct sputum microbiota,

72 older who were not previously identified as HIV-positive, children younger than 15 years who reporte

73 3878 (75.4%) people who were HIV-positive did not report antiretroviral therapy use,

74 HIV-positive donations were classified as recently acqui

75 We present three different scenarios where HIV-positive donor offers were evaluated for this one re

76 HIV-positive donor to HIV-positive recipient (HIV D+/R+)

77 list awaiting an organ offer, including from HIV-positive donors through the HIV Organ Policy Equity

78 e to receive a kidney or liver from deceased HIV-positive donors without active infections or neoplas

79 Excluding 12 children who tested HIV positive during follow-up, 461 HEU and 411 HU childr

80 ligible if they were aged 18 years or older, HIV positive, English speaking, and met criteria for alc

81 Human immunodeficiency virus (HIV)-positive gay and bisexual men (GBM) in Australia ar

82 the WHO HCV elimination target by 2025 among HIV-positive GBM in Australia is achievable.

83 nd behavioral changes on HCV incidence among HIV-positive GBM up to 2025 using a HCV transmission mod

84 ferative capacity parameters in the combined HIV-positive groups but not in the uninfected group.

85 y associated with monocyte activation in the HIV-positive groups, thereby suggesting a mechanism by w

86 and antiretroviral therapy (ART)-suppressed HIV-positive (HIV(+)) individuals.

87 Saharan African women and is prevalent among HIV-positive (HIV(+)) individuals.

88 l blood mononuclear cell (PBMC) samples from HIV-positive (HIV(+)) participants who received either s

89 icity (ADCC)-mediating antibodies present in HIV-positive (HIV(+)) sera, such as anti-coreceptor bind

90 orn, diabetic, human immunodeficiency virus (HIV)-positive, homeless, or incarcerated; and 2) enhance

91 among people who are non-US-born, diabetic, HIV-positive, homeless or incarcerated in California, Fl

92 Predictors of worse OS in patients who were HIV-positive included CTP ( P = .0071) and alpha-fetopro

93 ved HIV superinfection, which occurs when an HIV-positive individual becomes infected with a new dist

94 The prevalence of PDDIs in treated HIV positive individuals was assessed for the period: 01

95 in cohorts of human immunodeficiency virus (HIV)-positive individuals but have never been examined i

96 resistance in human immunodeficiency virus (HIV)-positive individuals on antiretrovirals.

97 ous studies in human immunodeficiency virus (HIV)-positive individuals on thymidine analogue backbone

98 We recruited HIV-positive individuals (aged >=18 years) from communit

99 Tau PET SUVRs were similar for HIV-positive individuals and HIV-negative control indivi

100 nd collection of tissues during autopsies of HIV-positive individuals are 2 proposed solutions to thi

101 Older HIV-positive individuals are not at increased risk of ta

102 ver, in the United States, less than half of HIV-positive individuals are retained in care.

103 graphy of migration networks and movement of HIV-positive individuals between communities is poorly u

104 mortality rates were the greatest comparing HIV-positive individuals having detectable HIV RNA and C

105 Viral suppression among HIV-positive individuals is essential for protecting hea

106 sted OR 0.88, 95% CI 0.68-1.14 [p=0.34]; for HIV-positive individuals OR 0.83, 0.65-1.05 [p=0.12]).

107 exosomes purified from either the saliva of HIV-positive individuals or the culture supernatants of

108 The median time from CHiP referral of HIV-positive individuals to ART initiation was approxima

109 This target aims for 90% of HIV-positive individuals to be aware of their status, fo

110 niversal home-based HIV testing, referral of HIV-positive individuals to government HIV clinic servic

111 national guidelines (Arm B), and revisits to HIV-positive individuals to support linkage to HIV care

112 A, of which 692 were sequential samples from HIV-positive individuals undergoing CrAg screening and a

113 sed the diagnostic accuracy of the CrAgSQ in HIV-positive individuals undergoing CrAg screening, dete

114 ART coverage among all HIV-positive individuals was approximately 85% in women

115 HIV-positive individuals who are 'retained in care' are

116 Among 1557 HIV-positive individuals who reported no prior ART at st

117 that the risk of TB disease is highest among HIV-positive individuals with severe vitamin D deficienc

118 th the same lymphoma type (16%; P < .001) or HIV-positive individuals without neoplasia or opportunis

119 tic Alzheimer disease, 15 cognitively normal HIV-positive individuals, and 17 cognitively impaired HI

120 Among HIV-positive individuals, none of the HIV-specific varia

121 the entire ART duration with mortality among HIV-positive individuals.

122 ive individuals, and 17 cognitively impaired HIV-positive individuals.

123 to achieving long-term viral suppression in HIV-positive individuals.

124 us constantly produced by lymphatic cells in HIV-positive individuals.

125 AM Ag positive) identified through screening HIV-positive inpatients with sputum and urine diagnostic

126 ve) TB patients identified through screening HIV-positive inpatients with sputum and urine diagnostic

127 14 HIV-positive to HIV-positive kidney and eight liver transplant recipient

128 n Policy Equity pilot study, HIV-positive to HIV-positive kidney and liver transplant recipients in t

129 ective, observational study, HIV-positive to HIV-positive kidney and liver transplant recipients were

130 Graft and patient survival among HIV-positive LT recipients have shown improvement over t

131 HIV-positive lymphoma patients with detectable EBV load

132 y of the cells in detection of even a single HIV-positive macrophage by fluorescence-assisted correla

133 Of the 247, 128 (49%) were HIV-positive; mean age was 30.80 years (standard deviati

134 In a separate cohort of 21 HIV positive men, we observed similar tissue distributio

135 The analysis identified 6001 HIV positive men-who-have-sex with men (MSMs) and 6077 H

136 Human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) are at ris

137 ions (HSIL) in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).

138 ncidence among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).

139 7; 95% confidence interval [CI] 2.5-8.9) and HIV-positive men (30% vs 11%; PR = 2.8; 95% CI, 1.9-4.1)

140 timated 95% of HIV-positive women and 85% of HIV-positive men knew their HIV status, and among these

141 f 287 HIV-positive women and 60 (46%) of 131 HIV-positive men were virally suppressed (<50 copies per

142 HIV-positive men who have sex with men (MSM) are at risk

143 ome countries, HIV-negative children born to HIV-positive mothers (HIV exposed, uninfected [HEU]) are

144 Infants of HIV-positive mothers can acquire HIV infection by variou

145 ers tested for HIV, only 39 (11%) of 371 had HIV-positive mothers.

146 MSM) including human immunodeficiency virus (HIV)-positive MSM be tested at least annually for syphil

147 ance with screening guidelines for high-risk HIV-positive MSM are warranted.

148 We classified HCV infections in HIV-positive MSM as either domestically or international

149 nts of male anal HPV16 infection, confirming HIV-positive MSM as priorities for anal cancer preventio

150 We examined the proportion of HIV-positive MSM tested for syphilis in the past 3, 6, a

151 Nearly one-third of sexually active HIV-positive MSM were not tested annually, and many at i

152 HIV-positive MSM were recruited from a longitudinal stud

153 HIV-positive MSM were screened for histopathological SIL

154 HIV-positive MSM were screened for histopathological SIL

155 e interval [CI]: 69%-73%) of sexually active HIV-positive MSM were tested for syphilis in the past ye

156 and HSIL were common during follow-up among HIV-positive MSM without dysplasia at baseline.

157 and HSILs were common during follow-up among HIV-positive MSM without dysplasia at baseline.

158 Of 193 HIV-positive MSM, 50 (26%) were diagnosed with anal HSIL

159 e men who have sex with men (MSM), and 12758 HIV-positive MSM.

160 Anal HPV16 prevalence was similar between HIV-positive MSW and HIV-negative MSM.

161 ative men who have sex with women (MSW), 924 HIV-positive MSW, 8213 HIV-negative men who have sex wit

162 diagnosis, the majority of patients who were HIV-positive (n = 65 [64%]) had been on antiretrovirals

163 tality rates between 2007 and 2017 among all HIV-positive New York City residents age 13+ by sex, usi

164 were 3,234 CVD deaths reported among 147,915 HIV-positive New Yorkers, with the proportion of deaths

165 ve men-who-have-sex with men (MSMs) and 6077 HIV positives non-MSMs (n=12078) living in DC, end of 20

166 h HIV and those without, with people who are HIV positive often excluded from using innovative therap

167 measured by proportion of people known to be HIV-positive or tested HIV-negative in the preceding 12

168 oncern in carefully monitored ART suppressed HIV-positive organ recipients.

169 One of the primary risks of HIV-positive to HIV-positive organ transplantation is loss of virologica

170 101 individuals were newly identified as HIV-positive out of 1248 total individuals who were HIV-

171 HIV RNA per milliliter) was assessed in all HIV-positive participants at 24 months.

172 population HIV viral load suppression in all HIV-positive participants increased from 34% (546 of 159

173 ategies, ART was initiated by 73 (91%) of 80 HIV-positive participants not on ART and PrEP was initia

174 ighty-nine HIV-negative participants and 252 HIV-positive participants under HAART were sampled.

175 HCV prevalence among HIV-positive participants was 50% (66 of 131 participant

176 ravenous Experience (ALIVE) Study, analyzing HIV-positive participants who had made a study visit in

177 ative participants (the uninfected group), 8 HIV-positive participants who were not receiving antiret

178 ART) (the infected, untreated group), and 15 HIV-positive participants who were receiving ART (the in

179 cantly greater increase in the percentage of HIV-positive participants with an HIV-1 RNA level of 400

180 The percentage of HIV-positive participants with viral suppression at 24 m

181 rapy (ART) coverage and HIV viral load among HIV-positive participants, and sexual behaviours and HIV

182 Among the HIV-positive participants, the correlation between tau P

183 elate with impairment or clinical markers in HIV-positive participants.

184 (false discovery rate Q value < 0.05) among HIV-positive participants.

185 heterosexual and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reporte

186 ss sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretr

187 eported by the HIV-negative partner, and the HIV-positive partner was virally suppressed (plasma HIV-

188 tive partner), and HIV-1 viral load testing (HIV-positive partner).

189 ing to conceive and in relationships with an HIV-positive partner.

190 itive respondents had a higher proportion of HIV-positive partners (66.4%, 95% confidence interval (C

191 er, those on PrEP had a higher proportion of HIV-positive partners than those not on PrEP (17.1% (95%

192 At baseline, median age for HIV-positive partners was 40 years (IQR 33-46) and coupl

193 , including antiretroviral therapy (ART) for HIV-positive partners, pre-exposure prophylaxis (PrEP) f

194 presence of the EBV load in the plasma of an HIV-positive patient can be an early predictor of lympho

195 HIV positive patients (33.8) had higher urogenital Cq va

196 sfully treated human immunodeficiency virus (HIV)-positive patients are poorly studied.

197 reduced among human immunodeficiency virus (HIV)-positive patients.

198 person-years in the sputum smear group) for HIV-positive patients (hazard ratio 0.76, 95% CI 0.60-0.

199 te that exosomes purified from the saliva of HIV-positive patients and secreted by HIV-infected T-cel

200 Reduction in mortality among HIV-positive patients in a secondary analysis suggests t

201 tients with HIV-infection, 1.8 (1.5-2.2) for HIV-positive patients on ART, and 4.2 (3.0-5.9) for HIV-

202 HIV-positive patients presented with HCC at a younger ag

203 HIV-positive patients receiving TDF/FTC have a lower ris

204 om clinical guidelines, and higher doses for HIV-positive patients should be considered to provide eq

205 y seroreversion (loss of seroresponse) among HIV-positive patients who have achieved seroresponses af

206 s a randomised controlled trial in ART-naive HIV-positive patients with CD4 cell count of more than 5

207 HIV-positive patients with lymphomas had more frequently

208 V load as biomarker and prognostic factor in HIV-positive patients with lymphomas.

209 as a biomarker and as a prognostic factor in HIV-positive patients with lymphomas.

210 ll survival and progression-free survival in HIV-positive patients with lymphomas.

211 is associated with lower odds of death among HIV-positive patients with multidrug-resistant tuberculo

212 itive patients on ART, and 4.2 (3.0-5.9) for HIV-positive patients with no or unknown ART.

213 his prospective cohort study, we followed 48 HIV-positive patients with PTB from South India before a

214 ded HIV-negative patients with lymphomas and HIV-positive patients without neoplasia or opportunistic

215 erase chain reaction in plasma samples of 81 HIV-positive patients' lymphomas at different moments: w

216 In HIV-positive patients, 30% higher doses are required to

217 In HIV-positive patients, CD4(+) T lymphocytes comprise a w

218 ding causes of non-AIDS-related mortality in HIV-positive patients, enhancing our understanding of HI

219 seminated tuberculosis is well documented in HIV-positive patients, the disease is poorly described a

220 Among 1,576 HIV-positive patients, vitamin D deficiency conferred a

221 tion of antiretroviral therapy (ART) for all HIV-positive patients.

222 two-dose HAV vaccination occurred in 3.9% of HIV-positive patients.

223 Deaths in HIV-positive people have decreased since the introductio

224 ortality associated with mental disorders in HIV-positive people in South Africa, adjusting for HIV t

225 At presentation, HIV-positive people were younger (median 56 versus 74 ye

226 diagnosed, is the major cause of death among HIV-positive people.

227 In this study, we observed that HIV-positive peripartum women who externally migrated an

228 to develop targeted interventions for mobile HIV-positive peripartum women.

229 of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving antiretroviral therapy (A

230 Of 77 590 HIV-positive persons receiving ART, 236 were diagnosed w

231 the oral bacterial community composition in HIV-positive persons under HAART to an HIV-negative grou

232 cant liver fibrosis was rare among ART-naive HIV-positive persons with high CD4 counts.

233 pare the oral microbiota of HIV-negative and HIV-positive persons, both with and without highly activ

234 aller populations with higher TB risk (e.g., HIV-positive persons, homeless persons) and ECI were gen

235 vision of these amongst both the general and HIV-positive population, however coverage remains low.

236 talizations in human immunodeficiency virus (HIV)-positive populations.

237 re deaths in people with mental disorders in HIV-positive populations, particularly in low-income and

238 etween Nov 22, 2012, and March 27, 2015, 726 HIV-positive pregnant women were included in the trial.

239 HIV-positive donor to HIV-positive recipient (HIV D+/R+) transplantation is pe

240 itive out of 1248 total individuals who were HIV-positive, representing an 8.1% previously unidentifi

241 HIV-positive respondents had a higher proportion of HIV-

242 4 couples were serodifferent, 149 (45%) were HIV-positive seroconcordant, and 23 (7%) were an HIV-pos

243 Significant negative interaction between HIV-positive serostatus and age on subclinical atheroscl

244 ssion was used to assess the associations of HIV-positive serostatus and FRS with subclinical atheros

245 HIV-positive status (adjusted prevalence ratio [aPR] 2.2

246 HIV-positive status (adjusted prevalence ratio [aPR] 2.2

247 dentify individuals who are unaware of their HIV-positive status and achieve testing saturation, we i

248 HIV status, that 90% of those who know their HIV-positive status are on antiretroviral therapy (ART),

249 tifying individuals who are unaware of their HIV-positive status in combination with monitoring the p

250 HIV-positive status was associated with an increased ris

251 p=0.16), but in those under 60 years of age HIV-positive status was associated with increased mortal

252 the mother (aOR 0.81 [0.68-0.98], p=0.027 vs HIV-positive status).

253 Detectable plasma EBV loads identified HIV-positive subjects that would eventually develop lymp

254 ounty Jail were enrolled-with enrichment for HIV-positive subjects-within 72hours of intake.

255 and venous blood samples of HIV-negative and HIV-positive subjects.

256 Likewise, HPV16 was significantly higher in HIV-positive than HIV-negative men, both among MSW (PR =

257 subclinical atherosclerosis was observed in HIV-positive than in HIV-negative individuals across the

258 equently represented isolated antigenemia in HIV-positive than non-HIV, immunocompromised patients (P

259 dge of HIV status (defined as self-reporting HIV positive to the community HIV care providers or acce

260 14 HIV-positive to HIV-positive kidney and eight liver tran

261 larger HIV Organ Policy Equity pilot study, HIV-positive to HIV-positive kidney and liver transplant

262 lticentre, prospective, observational study, HIV-positive to HIV-positive kidney and liver transplant

263 One of the primary risks of HIV-positive to HIV-positive organ transplantation is lo

264 We prospectively enrolled 102 HIV-positive Ugandans with probable or definite TBM from

265 1.6%; site range, 0.2%-3.4%) and was 3.1% in HIV-positive versus 1.1% among HIV-negative men.

266 ed prevalence ratio (PR) of comorbidities in HIV-positive versus HIV-negative admissions over time.

267 mortality ratio (SMR) for COVID-19 comparing HIV positive vs. negative adults using modelled populati

268 mulative day-28 mortality was similar in the HIV-positive vs. HIV-negative groups (26.7% vs. 32.1%; p

269 Median OS of patients who were HIV-positive was one half that of their HIV-uninfected c

270 rticipants for whom data were available were HIV-positive) were tested for tuberculosis with Xpert MT

271 tinue to have much higher rates of ESRD than HIV-positive whites, which could be attributed to the AP

272 Patients who were HIV positive with a baseline CD4 cell count of less than

273 The primary analysis compared HIV-positive with HIV-negative patients in terms of deat

274 study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline clinically significant porta

275 ients aged 18-60 years who were confirmed as HIV-positive within a maximum of the past 6 months and s

276 positive seroconcordant, and 23 (7%) were an HIV-positive woman and an unknown status male partner.

277 ILC frequencies were lowest in HIV positive women who experienced preterm birth.

278 were 46% (125/273) versus 11% (272/2588) in HIV-positive women (4.4, 3.7-5.3, p<0.0001).

279 r in women on ART when compared to untreated HIV-positive women (adjusted hazard ratio (aHR) 1.63, 95

280 ving ART were higher than those in untreated HIV-positive women (adjusted hazard ratio, 1.63; 95% con

281 vical HSIL; PR 23.1, 9.4-57.0, p<0.0001) and HIV-positive women (from 7% [105/1421] to 25% [25/101];

282 men; PR 12.9, 95% CI 6.7-24.8, p<0.0001) and HIV-positive women (from 8% [84/1094] to 17% [31/186]; 2

283 We recruited HIV-negative and HIV-positive women aged 30-65 years from a primary care

284 At enrolment, 176 (61%) of 287 HIV-positive women and 60 (46%) of 131 HIV-positive men

285 By the end of R3, an estimated 95% of HIV-positive women and 85% of HIV-positive men knew thei

286 s discuss viral load monitoring for pregnant HIV-positive women and those breastfeeding; ART treatmen

287 + T-cell count, pregnancy incidence rates in HIV-positive women receiving ART were higher than those

288 The overall prevalence among HIV-positive women was 1.3% (95% CI 0.8-1.9) for tobacco

289 sociodemographic status-compared to that of HIV-positive women who continuously resided within the s

290 years (5/20 in HIV-negative women, 12/52 in HIV-positive women).

291 nfecting maternal CMV strains, especially in HIV-positive women, and the large, recombinant CMV genom

292 While among HIV-positive women, the odds of being persistently infec

293 similar anal cancer risk profile to that of HIV-positive women.

294 36.7 per 100 person-years (29.1-46.3) among HIV-positive women.

295 n HIV-negative women and lowest in ART-naive HIV-positive women.

296 5.3% in HIV-negative women and 77.0-85.8% in HIV-positive women.

297 0-97.3) and specificity 59.9% (54.1-65.7) in HIV-positive women.

298 V infection in HIV-negative women but not in HIV-positive women.

299 HIV-negative women, and lowest in ART-naive HIV-positive women.

300 rsistent hrHPV infection in HIV-negative and HIV-positive women.